Pamish to supply mPEG-20k to UCB for Cimzia production

Pamish has signed a 6-year supply contract with Belgian pharmaceutical company UCB to provide mPEG-20k, a raw material for UCB's autoimmune disease drug Cimzia. The contract is effective from January 23, 2017, with automatic annual renewals thereafter.

“이번 계약은 UCB사의 자가면역질환 치료제 ‘심지아(Cimzia)’ 생산에 필요한 mPEG-20k를 공급하기 위한 것이다.”etoday.co.kr

• 1 source
• etoday.co.kr파미셀, 벨기에 다국적제약사 UCB와 mPEG-20k 공급계약 체결 - 이투데이Jan 23, 2017

Summarized from public sources; check the original articles before acting on it.